Actavis Buys Durata In Bolt-On Deal, Leaves Room For Transformation
This article was originally published in The Pink Sheet Daily
Actavis snaps up Durata for less than $1 billion, with significant contingent value tied to success of antibiotic Dalvance; meanwhile Actavis will likely continuing pursuing M&A.
You may also be interested in...
With a Special Protocol Agreement and an experienced sales team lined up, all the firm has to do now is get hospitals excited about an expensive antibiotic in a highly-genericized market.
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.